Studies have shown that roll-out of pre-exposure prophylaxis (PrEP) can significantly decrease HIV
incidence among men who have sex with men (MSM). However, cost, fear of side effects, as well as
a lack of preparation for “selling” this approach to those who could benefit have hampered PrEP
uptake at the global level. Also, the current event-driven (or “on demand”) PrEP regimen may be
complex for users: it requires a total of 4 pills to be taken over 3 days. Regimens with less pill burden
and complexities could contribute to a broader uptake.
A randomized, non-inferiority trial to compare the efficacy of event-driven PrEP using TAF/FTC
versus standard TDF/FTC in MSM in Thailand and France will be conducted in collaboration with
Hôpital Saint-Louis in Paris. This study is planned to start in 2022 and will be supported by the French
Agency for Research on AIDS and Viral Hepatitis (ANRS).